Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients

  • Authors:
    • Hiroki Osumi
    • Satoshi Matsusaka
    • Takeru Wakatsuki
    • Mitsukuni Suenaga
    • Eiij Shinozaki
    • Nobuyuki Mizunuma
  • View Affiliations

  • Published online on: August 31, 2015     https://doi.org/10.3892/mco.2015.630
  • Pages: 1295-1300
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The local renin-angiotensin system promotes angiogenesis and vascular proliferation via expression of vascular endothelial growth factor or epidermal growth factor receptor. We hypothesized that angiotensin II type‑1 receptor blockers (ARBs) in combination with bevacizumab (Bev) may improve clinical outcomes in patients with metastatic colorectal cancer (mCRC). A total of 181 patients with histopathologically confirmed mCRC treated with first‑line oxaliplatin‑based chemotherapy in combination with Bev were enrolled between June, 2007 and September, 2010. The patients were divided into two groups based on the presence or absence of treatment with ARBs prior to the initiation of second‑line chemotherapy. Kaplan‑Meier analysis and Cox proportional hazard modeling were used in the statistical analysis. the median progression‑free survival (PFS) in patients undergoing second‑line chemotherapy in combination with Bev and ARBs (n=56) vs. those treated in the absence of ARBs (n=33) was 8.3 vs. 5.7 months, respectively [hazard ratio (HR)=0.57, 95% confidence interval (CI): 0.35‑0.94, P=0.028]. the median overall survival (OS) was 26.5 vs. 15.2 months, respectively (HR=0.47, 95% CI: 0.25‑0.88, P=0.019). In the multivariate analysis, the use of ARBs was independently associated with prolongation of OS and PFS. In conclusion, the use of ARBs prolonged survival in mCRC patients.
View Figures
View References

Related Articles

Journal Cover

November 2015
Volume 3 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Osumi, H., Matsusaka, S., Wakatsuki, T., Suenaga, M., Shinozaki, E., & Mizunuma, N. (2015). Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Molecular and Clinical Oncology, 3, 1295-1300. https://doi.org/10.3892/mco.2015.630
MLA
Osumi, H., Matsusaka, S., Wakatsuki, T., Suenaga, M., Shinozaki, E., Mizunuma, N."Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients". Molecular and Clinical Oncology 3.6 (2015): 1295-1300.
Chicago
Osumi, H., Matsusaka, S., Wakatsuki, T., Suenaga, M., Shinozaki, E., Mizunuma, N."Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients". Molecular and Clinical Oncology 3, no. 6 (2015): 1295-1300. https://doi.org/10.3892/mco.2015.630